Erasca, Inc.
- Last sale
- Nov 12, 2026 · -5.90%
- Market cap
- $5.54B
- 350.96M shares
- Filings
- 357
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+9.0% FY25 yoy
- $5.54B
- —
- —
- 6.0×
- -1.72%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $92,854,000 | reported | |
| FY 2024 | 2024-12-31 | $115,359,000 | reported | |
| FY 2023 | 2023-12-31 | $103,821,000 | reported | |
| FY 2022 | 2022-12-31 | $112,457,000 | reported | |
| FY 2021 | 2021-12-31 | $73,922,000 | reported | |
| FY 2020 | 2020-12-31 | $29,550,000 | reported |
Pharmaceutical preparations
Erasca, Inc. is the 49th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
MIRMMirum Pharmaceuticals, Inc.$521.3M54.7%4.5%$6.1BMANEVeradermics, Inc———$5.7B
ERASErasca, Inc. (this company)———$5.5B
PTCTPTC Therapeutics, Inc.$1.7B114.5%39.4%$5.3BLQDALiquidia Corp$158.3M1,031.2%43.5%$5.2BDNTHDianthus Therapeutics, Inc.$2.0M67.3%7,973.3%$5.2BCOGTCogent Biosciences, Inc.———$5.1BTVTXTravere Therapeutics, Inc.$490.7M110.5%5.2%$5.0BAMRNAmarin Corp Plcuk$213.6M6.5%18.2%$4.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Erasca, Inc. · CIK 1761918 · Engraved from SEC EDGAR